维生素K1治疗对吸入污染合成大麻素后长效抗凝灭鼠剂对映体血浆浓度的影响
美国伊利诺伊州暴发合成大麻素相关凝血病和出血,归因于吸入被溴敌隆(BDF)、敌鼠(DiF)和溴鼠灵(BDL)污染的产品。该队列纳入32例患者,用UHPLC-MS/MS定量血浆LAAR及对映体。BDF检出31例,初始BDF、DiF、BDL血浆浓度分别为581±87、11.0±1.9、14.9±5.9 ng/mL,出院时BDF仍为453±68 ng/mL。BDF、DiF、BDL半衰期分别为7.5±1.3、7.2±1.9、1.8±0.3天;反式-BDF半衰期5.7±0.8天短于顺式7.6±1.9天。静脉维生素K1较口服使BDF半衰期更短、凝血病正常化更快;出院带维生素K1者再入院更少。作者提出随访时应同时监测血浆LAAR水平和凝血。
要点
- 32例LAAR中毒患者中BDF检出31例,30例同时含DiF、18例含BDL;初始BDF血浆浓度581±87 ng/mL。
- 出院时BDF血浆浓度仍达453±68 ng/mL,约为安全水平的40倍,尽管凝血已正常。
- BDF、DiF、BDL血浆半衰期分别为7.5±1.3、7.2±1.9、1.8±0.3天;反式-BDF 5.7±0.8天短于顺式7.6±1.9天。
- 静脉维生素K1较口服使BDF半衰期更短、凝血病正常化更快;出院带维生素K1者再入院更少。
- 作者提出LAAR中毒患者随访时应同时监测血浆LAAR水平和凝血。
适用人群与场景
- 吸入被BDF、DiF、BDL污染的合成大麻素后发生凝血病和出血的患者队列,共32例。
处置流程与药物剂量
- 标准治疗为高剂量维生素K1,原文提及静脉与口服两种给药途径,未给出具体剂量、频次或疗程。
- 出院时处方维生素K1者再入院更少。
- 作者提出随访期间同时监测血浆LAAR水平和凝血。
红旗征与不能漏的情况
- 凝血正常后过早停用维生素K1可致凝血病和出血复发,因出院时血浆LAAR仍高约40倍。
研究设计与关键结果
- 队列研究,32例患者,UHPLC-MS/MS定量血浆LAAR及对映体。
- BDF检出31例,其中30例同时含DiF、18例含BDL。
- 初始血浆浓度:BDF 581±87 ng/mL、DiF 11.0±1.9 ng/mL、BDL 14.9±5.9 ng/mL(均值±标准误)。
- 出院时BDF血浆浓度453±68 ng/mL。
- 半衰期:BDF 7.5±1.3天、DiF 7.2±1.9天、BDL 1.8±0.3天;反式-BDF 5.7±0.8天短于顺式-BDF 7.6±1.9天。
- 静脉维生素K1较口服维生素K1者BDF半衰期更短、凝血病正常化更快;出院带维生素K1者再入院更少。
证据类型、等级与局限
- 证据类型:队列研究(32例)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对LAAR中毒患者,凝血指标正常不代表毒物清除,出院时血浆LAAR仍可高约40倍,作者提出随访时同时监测血浆LAAR水平和凝血。
- 静脉维生素K1较口服使BDF半衰期更短、凝血病正常化更快;出院带维生素K1者再入院更少。
- 原文未给出维生素K1的具体剂量、频次和疗程,不能据此制定给药方案。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: An outbreak of synthetic cannabinoid (SC)-associated coagulopathy and bleeding in Illinois, USA was determined to be due to inhalation of SC contaminated with brodifacoum (BDF), difenacoum (DiF), and bromadiolone (BDL), highly potent long-acting anticoagulant rodenticides (LAARs). Treatment with high-dose vitamin K1 (VK1) prevented mortality; however, plasma LAAR levels were not measured risking recurrence of coagulopathy and bleeding due to premature discontinuation. The goal of this study was to determine if plasma LAAR levels were reduced following standard of care treatment to normalize coagulopathy.Methods: Blood samples were collected from a cohort of 32 patients, and ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) analysis used to quantify plasma LAAR levels including enantiomers.Results: BDF was detected in 31 samples; 30 also contained DiF and 18 contained BDL. Initial plasma levels were 581 ± 87, 11.0 ± 1.9, and 14.9 ± 5.9 ng/mL for BDF, DiF, and BDL, respectively (mean ± SE). At discharge plasma, BDF levels remained elevated at 453 ± 68 ng/mL. Plasma half-lives for BDF, DiF, and BDL were 7.5 ± 1.3, 7.2 ± 1.9, and 1.8 ± 0.3 days, respectively. The half-life for trans-BDF enantiomers (5.7 ± 0.8 days) was shorter than for cis-enantiomers (7.6 ± 1.9 days). BDF half-lives were shorter, and coagulopathy normalized faster in patients receiving intravenous VK1 as compared to oral VK1. Patients prescribed VK1 at discharge had fewer re-admittances.Conclusions: These results demonstrate that plasma LAAR levels at discharge were elevated in poisoned patients despite normal coagulation, and that the route of VK1 administration affected LAAR pharmacokinetics and INR normalization. We propose plasma LAAR levels and coagulation be monitored concomitantly during follow-up of patients with LAAR poisoning. KEY POINTSIn patients treated with high-dose vitamin K1 for LAAR poisoning, plasma levels remained 40-fold above safe levels upon discharge from hospital.LAAR half-lives, normalization of coagulopathy, and readmittances were reduced by treatment with intravenous vitamin K1.
参考来源
- Feinstein DL, Nosal DG, Ramanathan S, et al. Effects of vitamin K1 treatment on plasma concentrations of long-acting anticoagulant rodenticide enantiomers following inhalation of contaminated synthetic cannabinoids. Clin Toxicol (Phila). 2019. PMID: 31736367. doi:10.1080/15563650.2019.1687903
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。